Skip to content
The Lifesciences Magazine Logo
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us
Linkedin X-twitter Medium Reddit
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us
  • About Us
  • Magazines
  • Blogs
    • HealthTech
    • Lifesciences
    • Pharma
    • Healthcare
    • Fitness
    • Nutrition
  • Contact Us

Press Release

Enhanced Need for Hamas Pandemic Protection. Are You Prepared?

Enhanced Need for Hamas Pandemic Protection. Are You Prepared?

Look Out #3: What Must We Do Now to Prepare Israel and America for a Potential Bio War Sneak Attack?

Look Out #3: What Must We Do Now to Prepare Israel and America for a Potential Bio War Sneak Attack?

In this “Look Out #2” post and video, we ask and answer one of the most critical questions of our time: Why is it that right now, even though Israel is engaged in a vicious regional war, America is at greater risk than Israel if Israel Loses? It’s a different answer than you expect.

In this “Look Out #2” post and video, we ask and answer one of the most critical questions of our time: Why is it that right now, even though Israel is engaged in a vicious regional war, America is at greater risk than Israel if Israel Loses? It’s a different answer than you expect.

For reasons we will get into in future posts and videos, for now, we will ask only two critical questions: Are we missing the bigger picture regarding the precarious position of Israel? If so, why?

For reasons we will get into in future posts and videos, for now, we will ask only two critical questions: Are we missing the bigger picture regarding the precarious position of Israel? If so, why?

Challenges and Benefits of Implementing IDMP in the Pharmaceutical Industry

Challenges and Benefits of Implementing IDMP in the Pharmaceutical Industry

Former FDA Second-in-Command & COO and Harvard Faculty Member Dr. John Norris Speaks: It is A Race Against Time: Again, We Are Not Prepared for the Coming Catastrophe

Former FDA Second-in-Command & COO and Harvard Faculty Member Dr. John Norris Speaks: It is A Race Against Time: Again, We Are Not Prepared for the Coming Catastrophe

BI4ALL focuses on internationalisation and expects to grow 35% by 2022

BI4ALL focuses on internationalisation and expects to grow 35% by 2022

The Lifesciences Magazine Logo White

The Lifesciences Magazine is a global healthcare solutions platform that paves the way for various healthcare innovations, expert advice, and the success stories of professionals in the field who are driving transformation with their innovative thinking.

Linkedin X-twitter Medium Reddit

Category

  • Healthtech
  • Lifesciences
  • Pharma
  • Healthcare
  • Fitness
  • Nutrition

Newsletter

Send us a newsletter to get update

  • matthew@thelifesciencesmagazine.com
  • +1 (669) 303 8539
  • San Jose, California

Latest Updates

Shingrix Vaccine Linked to Lower Heart Attack and Stroke Risk | The Lifesciences Magazine

Shingrix Vaccine Linked To Lower Heart Attack And Stroke Risk

Dengue Cases Rise in Tampa Bay: 15 Local Cases Reported | The Lifesciences Magazine

Dengue Cases Rise In Tampa Bay As Infected Mosquitoes Test Positive

Thyroid Tablets Recalled Nationwide Over Superpotency Concerns Key Takeaway: Vitruvias recalled one lot of 30 mg thyroid tablets nationwide over potential superpotency concerns. Affected products: Lot No. 504950, NDC 69680-166-00, expiring Sept. 30, 2026. Patients should not stop treatment on their own and should contact their health care provider for guidance. Vitruvias Therapeutics Inc. is recalling one lot of 30 mg thyroid tablets nationwide after testing found they could be superpotent, the FDA said Aug. 24, potentially exposing patients to excessive thyroid hormone in the latest thyroid tablets recall to draw federal scrutiny. FDA identifies recalled thyroid tablets The recall covers Thyroid Tablets, USP 30 mg, lot No. 504950, with National Drug Code 69680-166-00 and an expiration date of Sept. 30, 2026. The affected lot was distributed nationwide in the United States from Jan. 31 through Sept. 30, 2025. Vitruvias released 3,655 units of the affected lot, with 1,955 sold, according to the FDA notice. The company is voluntarily recalling the product to the consumer level and has notified wholesalers to stop distributing it. The FDA listed the recall Aug. 24 after the company announced it Aug. 21. The agency said the recall is being conducted with its knowledge. Superpotency may cause health problems Testing confirmed the tablets have the potential to contain more thyroid hormone than intended. Taking superpotent thyroid tablets can cause hyperthyroidism, or an overactive thyroid, according to the FDA. Possible effects include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, and heart rhythm disturbances. The FDA said older adults, pregnant women and infants face greater risks, particularly with prolonged exposure. "Consumption of superpotent Thyroid tablets can cause hyperthyroidism," the FDA notice says, warning that excessive thyroid hormone can have serious effects on the heart and other body systems. Thyroid, USP is a natural thyroid preparation derived from porcine thyroid glands. It contains levothyroxine and liothyronine and is used to treat hypothyroidism, or an underactive thyroid, the condition this thyroid tablets recall is meant to safely treat. Patients should contact their providers Vitruvias said it has not received reports of adverse events known to be related to the recalled lot, according to the FDA. Patients taking the affected tablets should not stop treatment without first contacting their health care provider for guidance or a replacement prescription. Consumers with questions can contact Vitruvias Therapeutics at safety@vitruvias.com or 256-239-9373, Monday through Friday from 9 a.m. to 5 p.m. Central Time. The FDA also advises people who experience problems that may be related to the medicine to contact their health care provider and report adverse reactions through its MedWatch program. Anyone affected by this thyroid tablets recall should confirm their lot number before altering their routine.

Thyroid Tablets Recalled Nationwide Over Superpotency Concerns

Copyright ©2026: The Lifesciences Magazine | All rights reserved.
  • Disclaimer
  • Privacy Policy
  • Terms & Conditions

We use cookies to improve your experience and also collect some information using Google Analytics. By clicking “Accept “, you agree to this. You can find out more about our use of Cookies.

Accept & Close